Patients with normal left ventricular function who undergo elective unprotected left main coronary artery (ULMCA) percutaneous coronary intervention (PCI) with drug-eluting stents (DES) had favorable outcomes according to new research. Results of the multicenter, retrospective study are reported in the June issue of Catheterization and Cardiovascular Interventions, a journal published by Wiley-Blackwell on behalf of The Society for Cardiovascular Angiography and Interventions (SCAI).
For patients with ULMCA disease, coronary artery bypass grafting (CABG), known commonly as heart bypass surgery, is the standard of care based on medical evidence that shows a survival advantage with this intervention. Current guidelines for PCI state that ULMCA stenting may be an option for patients who are at high risk for adverse surgical outcomes, but have a low risk for procedural complications. In patients with severe aortic calcification, cerebrovascular disease, or limited life expectancy angioplasty may be elected over heart bypass surgery.
The present study, led by Michael Lee, MD, FSCAI, from the University of California, Los Angeles (UCLA) Medical Center evaluated the safety and efficacy of ULMCA PCI with DES in patients with normal left ventricular function. Researchers used data from a multicenter international registry, identifying 221 patients who underwent elective PCI for ULMCA disease between 2002 and 2009. Patients in the study had a mean age of 68 years and 75% were male; 25% had diabetes, 39% had a history of heart attack, and 40% had a prior PCI.
"Our analysis confirms that elective PCI with DES in patients with normal left ventricular function is a safe and effective treatment for ULMCA disease," said Dr. Lee. In the first 30 days following angioplasty no cardiac death, target lesion revascularization (TLR), stent thrombosis, or stroke were reported. While no cases of Q-wave myocardial infarction occurred, seven patients
|Contact: Dawn Peters|